title: [Use of the aluminum phosphate-binders in hemodialysis in the ultrapure water era].
abstract: BACKGROUND
  Aluminium binder has been ill-advised, but his use remain applicable in the clinique practice in very seleccionated and particular patients. The repercussion of prolonged treatment with low doses of aluminium phosphate-binders in haemodialysis was studied. The haemodialysis unit had a double osmosis inverse and the aluminium levels in haemodialysis liquid was less than 2 micrograms/liter.
  
  
  METHODS
  41 patients of the 295 on haemodialysis received aluminium phosphate-binders since the 2005 January to the 2007 November. The mean time of treatment was 17.8 months, and the doses was 3.9 tablets day (mean of 463 grams in the studied period). The association of low doses of aluminium phosphate-binders permitted a better control of phosphorus (6.8 to 4.8 mg/dl; p<0.0001), with a reduction of the others phosphate-binders: sevelamer (10.4 a 8 tablets/day; p<0.0001) and calcium phosphate-binders (4.6 to 3.1 tablets/day; p<0.0001). The serum aluminium increased after the aluminium treatment (6.8 to 13.8 mcg/l; p<0.0001), and no toxicity indirect signs were observed on CMV, haemoglobin, none PTH. Five patients (12.1%) reached aluminium serum levels higher 20 mcg/l, and none reached the 40 mcg/l.
  
  
  CONCLUSIONS
  The aluminium phosphate-binders were effective, economical and, now, with an apparent better security profile than in a previous time, but it is very important to be careful with this use and to follow a vigilance strict on patients and haemodialysis liquid.
authors.affiliation: Hospital Perpetuo Socorro, Alicante. lola@olemiswebs.com
authors.forename: Maria D
authors.initials: MD
authors.lastname: Arenas
authors.forename: T
authors.initials: T
authors.lastname: Malek
authors.forename: M T
authors.initials: MT
authors.lastname: Gil
authors.forename: A
authors.initials: A
authors.lastname: Moledous
authors.forename: C
authors.initials: C
authors.lastname: Núñez
authors.forename: F
authors.initials: F
authors.lastname: Alvarez-Ude
mesh_terms: D000368:Aged; D000536:Aluminum Hydroxide / Q000627:therapeutic use*; D002614:Chelating Agents / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D054559:Hyperphosphatemia / Q000209:etiology / Q000517:prevention & control*; D008297:Male; D010710:Phosphates / Q000378:metabolism; D006435:Renal Dialysis / Q000009:adverse effects
chemical_list: D002614:Chelating Agents; D010710:Phosphates; D000536:Aluminum Hydroxide